New research article demonstrates production and efficacy potential for novel cVLP/S1-based COVID-19 vaccine
A recent article published in mBio (American Society for Microbiology) illustrates how the cVLP vaccine developed by AdaptVac and University of Copenhagen has successfully been produced using a robust production platform providing scalability, low cost, and safety.Attana technology has been applied by the team of Prof Ali Salanti at the University of Copenhagen in their development of a COVID-19 vaccine based on the patented Capsid Virus-Like Particle (cVLP) technology. The recently published mBio article is titled, “Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain